Skip to main content
Advertisement
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

May 10, 2024

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

De-Shen Wang and colleagues evaluate the efficacy and safety of cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as a conversion regimen in patients with colorectal cancer and initially unresectable colorectal liver metastases.

Image credit: Ivan Samkov, Pexels

04/16/2024

Editorial

Mixed progress in global tobacco control

In this piece, Coral Gartner and Wayne Hall discuss ongoing efforts to reduce the global burden of tobacco-related disease and disability and the relative success of WHO-recommended tobacco control measures.

Mixed progress in global tobacco control

Image credit: Uitbundig, Pexels

Get new content from PLOS Medicine in your inbox

Thank you! You have successfully subscribed to the PLOS Medicine newsletter.

Sorry, an error occurred while sending your subscription. Please try again later.

Try again
PLOS Medicine | ISSN: 1549-1676 (online)